Evofem Bioscienc Stock Price, News & Analysis

Evofem Biosciences (NASDAQ: EVFM) reported promising results from its "House Rules" DTC campaign featuring Annie Murphy, aimed at promoting Phexxi, a hormone-free contraceptive. The campaign has achieved 2 billion media impressions and led to a 263% increase in website traffic. Key metrics show a 71% rise in sales and a 56% increase in new users for Phexxi in September compared to August 2021. Over 8,900 units of Phexxi were dispensed, with 7,839 prescriptions issued. The campaign targets women seeking alternatives to hormonal contraceptives.

Evofem Biosciences has announced a registered direct offering of 10,000 shares of Series B Convertible Stock at $1,000 per share, totaling approximately $10 million in gross proceeds. The sale will close in two tranches, with the initial closing occurring shortly after the announcement. Funds will support Phexxi® commercialization, the Phase 3 clinical trial 'EVOGUARD' for preventing chlamydia and gonorrhea, and general corporate purposes. The offering is part of Evofem's strategy to enhance shareholder value and maintain cash flow into Q1 2022.

Evofem Biosciences, Inc. (NASDAQ: EVFM) praised House leaders for advocating coverage of all FDA-approved contraceptives under the Affordable Care Act (ACA). CEO Saundra Pelletier recognized the importance of the House's letter, which requests senior Biden Administration officials to ensure compliance with ACA requirements. The company's product, Phexxi, is a hormone-free contraceptive gel approved by the FDA in May 2020. Evofem focuses on women's reproductive health solutions, including contraception and protection against STIs.

Evofem Biosciences (NASDAQ: EVFM) announced its CEO, Saundra Pelletier, will present at the LD Micro Main Event in Los Angeles from October 12-14, 2021. The presentation is scheduled for October 12 at 12:30 p.m. PT. The company recently launched a new campaign, "House Rules," on September 9, 2021, to promote its hormone-free contraceptive, Phexxi. The campaign has successfully increased media coverage, site traffic, and telehealth visits, enhancing Phexxi prescription growth. Interested parties can register for the virtual presentation via the company website.

Evofem Biosciences, Inc. (NASDAQ: EVFM) announced the publication of a manuscript in Advances in Therapy, discussing variability in contraceptive clinical trial designs and their impact on efficacy outcomes. The study highlights challenges in comparing efficacy across non-hormonal and hormonal contraception due to variations in trial protocols. Key findings show that the exclusion of certain menstrual cycles can misrepresent the effectiveness of contraceptives. The paper aims to raise awareness among healthcare providers regarding these nuances, thereby improving contraceptive counseling.

Evofem Biosciences (NASDAQ: EVFM) announced the presentation of seven clinical trial data sets on its products, Phexxi and EVO100, at four medical society meetings in October 2021. Leading the presentations is Dr. Brandi Howard, who highlighted significant interest from healthcare providers. The posters will cover topics including genitourinary symptoms and the effectiveness of the vaginal pH modulator in preventing STIs. Notably, the AMPREVENCE study showcased statistically significant reductions in the risk of chlamydia and gonorrhea infections. The abstracts will be published in relevant medical journals.

Evofem Biosciences (NASDAQ: EVFM) announced that CEO Saundra Pelletier will participate in two investor conferences. The first is the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, featuring a corporate presentation at 7:00 a.m. ET. The second is the Morgan Stanley Virtual Global Healthcare Conference on September 14, 2021, in a fireside chat at 12:30 p.m. ET. Both events will be webcast and available for 30 days on the company’s website. Evofem focuses on women's sexual and reproductive health, including innovative contraceptive solutions.

Evofem Biosciences (NASDAQ: EVFM) reported a net loss of $33.4 million, improving from $46.2 million in Q1 2021. Phexxi sales surged by 68% to $1.9 million, with a 47% increase in prescriptions and a 52% growth in prescriber base. Operating expenses fell by 6% to $43 million, despite a 17% rise in R&D costs to $8.5 million. A celebrity campaign is set to launch in September 2021 to boost brand awareness. Cash and equivalents stood at $47 million as of June 30, 2021. The company remains on track for the EVOGUARD trial completion by year-end.